[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-variceal-upper-gastrointestinal-bleeding\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-variceal-upper-gastrointestinal-bleeding":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100652613","keverprazan-vs-pantoprazole-for-the-treatment-of-anvugib-100652613",false,"NCT07776730","Keverprazan vs Pantoprazole for the Treatment of ANVUGIB","Keverprazan Versus Pantoprazole for the Treatment of Acute Non Variceal Upper Gastrointestinal Bleeding: Protocol of a Prospective, Multicenter, Non Inferiority, Randomized Controlled Trial","Inclusion criteria are as follows:\n\n1. Participants presented with hematemesis, melena, or other clinical manifestations suggestive of upper gastrointestinal bleeding within 5 days before screening.\n2. Participants have endoscopic confirmation of a non-variceal source of upper gastrointestinal bleeding.\n3. Participants are aged between 18 and 75 years.\n4. Participants who are willing to participate in this clinical trial and sign the written informed consent.\n\nExclusion criteria are as follows:\n\n1. Participants have experienced failure of endoscopic hemostasis, rebleeding before randomization, or a requirement for immediate transcatheter arterial embolization or surgery at the time of eligibility assessment.\n2. Participants have an active malignancy or malignancy expected to interfere with survival, outcome assessment, treatment adherence, or follow-up.\n3. Participants have esophageal or gastric varices or portal hypertensive gastropathy identified during endoscopic examination.\n4. Participants who are unable to swallow the study medication.\n5. Participants have a history of partial or total gastrectomy, gastric bypass surgery, or other major surgery.\n6. Severe organ dysfunction, including any of the following: Severe hepatic or renal impairment; Unstable or severe cardiovascular, respiratory, neurological, or other systemic disease.\n7. Zollinger-Ellison syndrome.\n8. Any contraindication to keverprazan or pantoprazole, including known hypersensitivity to either medication or any of their components.\n9. Pregnancy or lactation.\n10. Participation in another clinical study within 3 months before enrollment.\n11. Other situations considered by the investigator as unsuitable for enrollment.","ALL","18 Years","75 Years",{"count":20,"type":21},908,"ESTIMATED","INTERVENTIONAL",[24],"NA","Acute non-variceal upper gastrointestinal bleeding (ANVUGIB) is a common medical emergency requiring hospitalization. The cornerstone of ANVUGIB management is effective gastric acid suppression. Potassium-competitive acid blockers (P-CABs) represent a novel class of gastric acid secretion inhibitors, which can rapidly and consistently increase intragastric pH. Keverprazan, a novel P-CAB, has been shown to be effective in treating duodenal ulcers and erosive esophagitis. Herein, we have designed a multicenter randomized controlled trial (RCT) to determine whether keverprazan is noninferior to pantoprazole in preventing rebleeding after successful initial hemostasis in patients with ANVUGIB.",[27],"Non-variceal Upper Gastrointestinal Bleeding",[29,30,31,32,33],"non-variceal upper gastrointestinal bleeding","proton pump inhibitors","potassium-competitive acid blockers","keverprazan","pantoprazole","NOT_YET_RECRUITING","2026-08-17",{"date":37,"type":38},"2026-08-20","ACTUAL",{"date":40,"type":21},"2026-10-01",{"date":42,"type":21},"2029-12-30",{"name":44,"class":45},"General Hospital of Shenyang Military Region","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":5},"100613026","the-difference-in-carbon-footprint-between-diagnostic-upper-gi-endoscopy-in-dyspeptic-patients-versus-therapeutic-upper-gi-bleeding-100613026","NCT07261228","The Difference in Carbon Footprint Between Diagnostic Upper GI Endoscopy in Dyspeptic Patients Versus Therapeutic Upper GI Bleeding","THE DIFFERENCE IN CARBON FOOTPRINT BETWEEN DIAGNOSTIC UPPER GI ENDOSCOPY IN DYSPEPTIC PATIENTS VERSUS THERAPEUTIC UPPER GI BLEEDING","Inclusion Criteria:\n\n* Patients with dyspepsia or non-variceal upper GI bleeding\n* Age 20-80 years\n* Body mass index of 30 or less;\n* Receiving one of the following procedure during upper GI endoscopy:\n\nFor diagnostic endoscopy: Rapid urease test for H. pylori infection For therapeutic endoscopy: stop bleeding with either Argon plasma coagulation or Bipolar hemostasis probe or Hemostasis clip\n\nExclusion Criteria:\n\n* Platelet \\\u003C 50,000\n* INR \\> 2.5\n* Pregnancy\n* History of allergy to IV sedative medication\n* Peptic ulcer grade IIc and III according to Forrest classification\n* Patient receiving inhalation anesthesia","20 Years","80 Years",{"count":57,"type":21},75,"OBSERVATIONAL","The goal of this observational study is to learn about the carbon footprint produced from diagnostic upper GI endoscopy in patients with dyspepsia and therapeutic upper GI endoscopy in patients with non-variceal upper GI bleeding. The main question it aims to answer is:\n\n• How much carbon footprint is generated from upper GI endoscopy Participants are already receiving diagnostic and therapeutic upper GI endoscopy as part of their regular medical care for dyspepsia and non-variceal upper GI bleeding, respectively. The carbon footprint generated from this treatment process is examined.",[61,62,27],"Carbon Footprint in Upper GI Endoscopy","Dyspepsia",[64,65,66,62,67],"Carbon footprint","Upper GI endoscopy","EGD","Non-variceal upper gastrointestinal bleeding","RECRUITING","2025-11-21",{"date":71,"type":38},"2025-12-03",{"date":73,"type":38},"2025-06-01",{"date":75,"type":21},"2025-12-31",{"name":77,"class":45},"King Chulalongkorn Memorial Hospital"]